Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Nu Skin Enterprises reported fourth-quarter and full-year 2025 results within guidance, with profitability improving despite lower sales. 2025 revenue was $1.49 billion, down 14.3% from 2024, while diluted EPS rose to $3.18 (or $1.27 excluding the Mavely gain and other charges) from a loss of $(2.95).
Fourth-quarter revenue was $370.3 million, down 16.9%, but EPS improved to $0.29 from $(0.73) as gross margin expanded and restructuring costs fell. Customers declined 10%, and sales leaders fell 19%. For 2026, the company guides revenue to $1.35–$1.50 billion and EPS of $0.80–$1.20, expecting a return to year-over-year revenue growth by year-end driven by its Prysm iO wellness platform and an anticipated India market launch.
Charles Schwab Investment Management Inc. has reported a beneficial ownership stake in Nu Skin Enterprises, Inc. Class A common stock. The firm holds 2,621,785 shares, representing 5.37% of the class as of the event date 12/31/2025.
Schwab reports sole power to vote and dispose of all 2,621,785 shares, with no shared voting or dispositive power. It certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Nu Skin.
Nu Skin Enterprises executive reports share withholding for taxes
Nu Skin Enterprises, Inc. officer Chayce Clark, who serves as EVP and General Counsel, reported a transaction in the company’s Class A common stock on 12/20/2025. A total of 9,049 shares were disposed of at a price of $10.27 per share, coded as an “F” transaction, which indicates shares were withheld by the company to satisfy tax withholding obligations tied to vesting of previously granted restricted stock units. After this tax-related withholding, Clark beneficially owned 224,091 shares of Nu Skin Class A common stock in direct ownership.
Nu Skin Enterprises director reports small share increase through plan dividend
A Nu Skin Enterprises, Inc. director filed a Form 4 reporting the acquisition of 10 shares of Class A common stock on 12/10/2025 at a price of $10.35 per share. The filing states these shares were acquired through dividend reinvestment under the company’s Deferred Compensation Plan in accordance with the plan’s terms. Following this transaction, the director beneficially owns 42,979 shares, held directly. This is a routine insider ownership update showing plan-based reinvestment rather than an open-market trade.
Nu Skin Enterprises (NUS) insider transaction: Chief Product Officer Steven Hatchett reported buying 5,500 shares of Class A Common Stock on 11/11/2025 at $9.61 per share, according to a Form 4 filing.
Following the purchase, Hatchett beneficially owns 167,565 shares, held directly. The filing was signed by attorney-in-fact Gregory Belliston on 11/12/2025.
Nu Skin Enterprises (NUS) reported Q3 2025 results. Revenue was $364.2 million, down 15% year over year as macro headwinds weighed on demand and field activity. Operating income rose to $21.6 million from $18.2 million. Net income was $17.1 million ($0.34 diluted EPS) versus $8.3 million a year ago.
For the first nine months of 2025, revenue was $1,114.8 million, down 13% year over year. Net income reached $145.7 million, reflecting a $176.2 million gain on the January sale of the Mavely business. Core costs were lower: selling and G&A declined versus last year, and restructuring charges were significantly lower than 2024.
The balance sheet strengthened. Cash and cash equivalents were $251.8 million versus $186.9 million at year-end 2024. Long-term debt fell to $209.0 million from $363.6 million, aided by $220.0 million of debt payments year-to-date, including a $115.0 million term-loan paydown funded by sale proceeds. The company paid quarterly dividends of $0.06 per share and repurchased $10.0 million of stock year to date, with $152.4 million remaining under the authorization. As of November 1, 2025, 48,750,076 Class A shares were outstanding.
Nu Skin Enterprises (NUS) furnished an 8‑K announcing it issued a press release with financial results for the three‑ and nine‑month periods ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act. The report lists Class A Common Stock trading on the NYSE and is signed by CFO James D. Thomas.
Edwina D. Woodbury, a director of Nu Skin Enterprises, Inc. (NUS), reported an acquisition of Class A common stock on 09/10/2025. The filing shows shares were acquired at a price of $11.52 under the company’s Deferred Compensation Plan via dividend reinvestment. Following the transaction, Ms. Woodbury beneficially owns 42,969 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025. The filing lists the transaction as a direct ownership change and notes the dividend reinvestment as the reason for the share increase.
Laura Nathanson, a director of Nu Skin Enterprises (NUS), reported a sale of 6,489 shares of Class A common stock on 09/04/2025 at a price of $12.22 per share. After the transaction she beneficially owns 33,149 shares, reported as directly held. The Form 4 was signed by an attorney-in-fact on her behalf.
Nu Skin Enterprises insider sale summary. EVP and General Counsel Chayce Clark reported a sale of 20,000 shares of Class A common stock on 09/03/2025 at a weighted-average price of $11.97 per share. After the reported disposition, the reporting person beneficially owned 233,140 shares, held directly. The Form 4 shows no derivative transactions and was signed by an attorney-in-fact on behalf of the reporting person on 09/04/2025. The filing includes an explanation that the reported price is a weighted average from multiple trades between $11.96 and $12.01.